Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Operating Income: 2012-2025

Historic Operating Income for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $36.2 million.

  • Ani Pharmaceuticals' Operating Income rose 276.62% to $36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.9 million, marking a year-over-year increase of 515.57%. This contributed to the annual value of $584,000 for FY2024, which is 98.76% down from last year.
  • Ani Pharmaceuticals' Operating Income amounted to $36.2 million in Q3 2025, which was up 160.87% from $13.9 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Operating Income registered a high of $36.2 million during Q3 2025, and its lowest value of -$23.7 million during Q4 2021.
  • In the last 3 years, Ani Pharmaceuticals' Operating Income had a median value of $12.4 million in 2023 and averaged $11.3 million.
  • In the last 5 years, Ani Pharmaceuticals' Operating Income slumped by 7,267.07% in 2021 and then soared by 459.32% in 2023.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Operating Income stood at -$23.7 million in 2021, then skyrocketed by 107.67% to $1.8 million in 2022, then soared by 269.56% to $6.7 million in 2023, then crashed by 165.09% to -$4.4 million in 2024, then soared by 276.62% to $36.2 million in 2025.
  • Its Operating Income was $36.2 million in Q3 2025, compared to $13.9 million in Q2 2025 and $26.2 million in Q1 2025.